STOCK TITAN

Tarsus Pharmaceuticals Inc - TARS STOCK NEWS

Welcome to our dedicated news page for Tarsus Pharmaceuticals (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tarsus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tarsus Pharmaceuticals's position in the market.

Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) to host live webcast for Q3 2023 financial results and corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences earnings
-
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. announces launch of XDEMVY™ for prescription, CEO to ring closing bell at Nasdaq Stock Market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
fda approval
-
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. announces participation in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
conferences
Rhea-AI Summary
Tarsus Pharmaceuticals announces availability of XDEMVY for Demodex blepharitis treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.99%
Tags
offering
-
Rhea-AI Summary
Tarsus Pharmaceuticals has received FDA approval for XDEMVY, the first and only treatment for Demodex blepharitis. XDEMVY targets the root cause of the disease and has shown efficacy in clinical trials. It is expected to be available by prescription by the end of August 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.82%
Tags
fda approval
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
conferences
Rhea-AI Summary
Tarsus Pharmaceuticals announced financial results for Q1 2023 and recent business achievements. They are preparing for the potential launch of TP-03, the first FDA-approved treatment for Demodex blepharitis. They also provided updates on their pipeline studies and disease education campaigns. Q1 net loss was $23.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
earnings
Tarsus Pharmaceuticals Inc

Nasdaq:TARS

TARS Rankings

TARS Stock Data

1.30B
24.39M
4.35%
89.26%
17.63%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Irvine

About TARS

tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.